Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports
The revised ICH guideline on post-approval safety data, endorsed at Step 4 on 15 September 2025. E2D(R1) modernises the 2003 E2D: it keeps the harmonised definitions and expedited-reporting standards for post-approval individual case safety reports, and updates the treatment of solicited sources such as patient support programmes and market research programmes, and of digital-media safety information, to reflect how safety data actually reach marketing authorisation holders today.
What this does not cover
stated in the document's own scope- Covers post-approval safety data; safety reporting during clinical development remains under ICH E2A and regional trial regulations.
- Defines case management and reporting standards; the electronic message format for transmitting ICSRs is specified by E2B(R3).
- Addresses individual case safety reports; aggregate periodic reporting is the province of E2C(R2) and regional PSUR requirements.
- Sets harmonised principles; the binding reporting clocks in each region come from regional law, such as 21 CFR 314.80/600.80 and the EU pharmacovigilance legislation.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH E2D(R1) is the harmonised guideline for managing safety data after a medicine is approved: the definitions, the sources, and the expedited-reporting standards for post-approval individual case safety reports. It carries forward the framework of the 2003 E2D — post-approval definitions of adverse event and adverse reaction, seriousness, and expectedness; the split between unsolicited sources (spontaneous reports, literature, the internet and digital media) and solicited sources (organised data-collection systems such as patient support programmes); the standards for what makes a case valid and reportable; and good case management practices. The revision modernises the treatment of solicited sources and digital-media safety information to match how safety data reach marketing authorisation holders today.
Scope & applicability
Post-approval safety data management by marketing authorisation holders and regulators in ICH regions — the sources, validation, and expedited reporting of ICSRs for marketed products. Clinical-trial safety reporting remains under E2A; electronic transmission is specified by E2B(R3). In the EU it applies within the legal framework from 18 March 2026.
Legal basis & how it acquires force
An ICH harmonised guideline, endorsed by the Regulatory Members of the ICH Assembly at Step 4 on 15 September 2025, which commits ICH regulators to regional implementation (Step 5). It supersedes the E2D guideline of 2003. In the EU it is implemented through the EMA and applies within the legal framework from 18 March 2026; other ICH members implement it through their own instruments, as the FDA does by issuing ICH guidelines as guidance for industry.
Document structure
| Part | Covers |
|---|---|
| Introduction and scope | Objectives and the post-approval setting the guideline addresses |
| Definitions | Adverse event, adverse reaction, serious, and expectedness in the post-approval context |
| Sources of individual case safety reports | Unsolicited sources — spontaneous reports, literature, digital media — and solicited sources such as patient support programmes |
| Standards for expedited reporting | What constitutes a valid, reportable case and the harmonised timelines for serious unexpected reactions |
| Good case management practices | Case validity, follow-up, duplicate detection, and the quality of case narratives |
Key requirements
- Apply the harmonised post-approval definitions of adverse event, adverse reaction, serious, and expectedness
- Handle unsolicited sources (spontaneous reports, literature, digital media) and solicited sources (e.g. patient support programmes) per their distinct rules
- Expedite valid cases that are serious and unexpected within the harmonised timelines
- Follow good case management practices: case validity, follow-up, duplicate detection, and quality of narratives
Implementation tips
- Re-map every solicited-source programme (PSPs, market research) against the R1 text — source classification drives whether causality is assumed or must be reported
- Plan the EU transition against the 18 March 2026 application date and the corresponding GVP module updates
Revision notes
E2D(R1) reached ICH Step 4 on 15 September 2025 and supersedes the 2003 E2D guideline; the EU applies it from 18 March 2026.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
E2D(R1) is the post-approval member of the ICH E2 safety family: E2A supplies the clinical-development definitions and expedited-reporting standards, E2B(R3) the electronic ICSR transmission format, and E2C(R2) the periodic benefit-risk evaluation report. In the EU its subject matter is operationalised through GVP Module VI on the management and reporting of adverse reactions; in the US the parallel regulations are 21 CFR 314.80 for drugs and 21 CFR 600.80 for biologics.
ICH E2D(R1): frequently asked questions
Quick answers to common questions about ICH E2D(R1).
What changed between ICH E2D and E2D(R1)?
E2D(R1), endorsed at Step 4 on 15 September 2025, supersedes the 2003 guideline. It retains the post-approval definitions, source classification, expedited-reporting standards, and good case management practices, and updates the handling of solicited sources — such as patient support and market research programmes — and of safety information arising from digital media.
When does E2D(R1) apply in the EU?
The EMA published the guideline for application within the European legal framework from 18 March 2026, following its Step 4 endorsement in September 2025.
What is the difference between solicited and unsolicited sources?
Unsolicited sources are reports that arrive without prompting — spontaneous reports from healthcare professionals or patients, published literature, and digital media. Solicited sources are organised data-collection systems, such as patient support programmes. The distinction matters because it drives how causality is handled and which cases qualify for expedited reporting.
How does E2D(R1) relate to E2A?
E2A defines safety-reporting definitions and expedited timelines for the clinical-trial period; E2D(R1) is its post-approval counterpart, adapting definitions and reporting standards to marketed products, where reports arrive spontaneously rather than from controlled studies.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.